Hepatitis C Group Rejects Settlement Offer By Japanese Government, Drug Makers (Japan)
This article was originally published in PharmAsia News
A group of people infected with hepatitis C after receiving contaminated blood has rejected a settlement agreement offered by drug makers and the Japanese government. The group is comprised of 13 patients out of an estimated 200 plaintiffs who contracted the disease after receiving the blood. The 13-member group said it rejected the offer because it would not properly compensate some of the 200. (Click here for more
You may also be interested in...
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.
CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.